Kanunlarda Öğrenim Hakkı

A mortalidade cardiovascular é a principal causa de morte nos doentes em diálise. Até ao momento atual, muito poucas intervenções terapêuticas se associaram a uma redução da mortalidade, e isto verificou -se apenas em ensaios clínicos com reduzido número de participantes. O candesartan associou -se à redução de eventos cardiovasculares27_{, o carvedilol}

reduziu a mortalidade em doentes com cardiomiopatia28 _{e o sevelamer reduziu a mortalidade}

num grupo de 127 doentes em diálise com hiperfosfatemia12_.

A presença de calcifi cações vasculares é um sinal de alerta para um elevado risco cardiovascular nos doentes renais crónicos. Nestes doentes justifi ca -se a intervenção terapêutica em todos os fatores associados ao desenvolvimento e progressão das calcifi cações vasculares, sendo a correção das alterações do metabolismo fosfocálcico um dos campos de atuação.

Esperamos que o progressivo conhecimento dos múltiplos mecanismos fi siopatológicos na base do desenvolvimento das calcifi cações vasculares permitam alargar o campo de intervenção terapêutica nos nossos doentes. Será sempre necessário confi rmar se este tipo de intervenção terapêutica se associa à redução da morbilidade e da mortalidade nestes doentes.

Referências

1. Adragão T, Frazão JM. Cardiovascular risk in dialysis patients: an X -ray vision on vascular calcifi cations. Kidney Int 2008; 74(12):1505 -1507.

2. Adragão T. Evaluation of vascular calcifi cations in CKD patients. Int J Artif Organs 2009;32(2):81-

-86.

3. Adragão T, Ferreira A, Frazão J. Evaluación no invasiva de la calcifi cación vascular en pacientes con ERC. (Aceite para publicação no livro “Alteraciones del metabolismo óseo -mineral en la enfermedad renal crónica”, editado pelo Prof. Jorge Cannata).

4. Braun J, Oldendorf M, Moshage W, et al. Electron beam computed tomography in the evaluation of cardiac calcifi cation in chronic dialysis patients. Am J Kidney Dis 1996; 27:394 -401.

5. Blacher J, Guerin AP, Pannier B, et al. Arterial calcifi cations, arterial stiffness, and cardiovascular risk in end -stage renal disease. Hypertension 2001;38:938 -942.

6. Moe SM, O’Neill KD, Fineberg N, et al. Assessment of vascular calcifi cation in ESRD patients using spiral CT. Nephrol Dial Transplant 2003; 18: 1152 -1158.

7. London GM, Guerin AP, Marchais SJ, et al. Arterial media calcifi cation in end -stage renal disease: impact on all -cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731- -1740.

8. Adragão T, Pires A, Lucas C, Birne R, Magalhães L, Gonçalves M, Negrão AP. A simple vascular calcifi cation score predicts cardiovascular risk in haemodialysis patients. Nephrol Dial Transplant 2004;19(6):1480 -1488.

9. Wexler L, Brundage B, Crouse J, et al. Coronary artery calcifi cation: Patophysiology, epidemiology, imaging methods and clinical implications. A statement for health professionals from the American Heart Association. Circulation 1996; 94: 1175 -1192.

10. Haydar AA, Hujairi NM, Covic AA, et al. Coronary artery calcifi cation is related to coronary atherosclerosis in chronic renal disease patients: a study comparing EBCT -generated coronary artery calcium scores and coronary angiography. Nephrol Dial Transplant 2004; 19: 2307 -2312. 11. Gross ML, Meyer HP, Ziebart H, et al. Calcification of coronary intima and media:

immunohistochemistry, backscatter imaging, and x -ray analysis in renal and nonrenal patients. Clin J Am Soc Nephrol 2007;2(1):121 -134.

12. Block GA, Raggi P, Bellasi A, et al. Mortality effect of coronary calcifi cation and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007;71(5):438 -441.

13. Matsuoka M, Iseki K, Tamashiro M, et al. Impact of high coronary artery calcifi cation score (CACS) on survival in patients on chronic hemodialysis. Clin Exp Nephrol 2004; 8(1):54 -58.

126

14. Wang AY, Wang M, Woo J, et al. Cardiac valve calcifi cation as an important predictor for all -cause mortality and cardiovascular mortality in long -term peritoneal dialysis patients: a prospective study. J Am Soc Nephrol 2003;14(1):159 -168.

15. Varma R, Aronow WS, McClung JA, et al. Prevalence of valve calcium and association of valve calcium with coronary artery disease, atherosclerotic vascular disease, and all -cause mortality in 137 patients undergoing hemodialysis for chronic renal failure. Am J Cardiol 2005; 15;95(6):742 -743. 16. Sharma R, Pellerin D, Gaze DC, et al. Mitral annular calcifi cation predicts mortality and coronary

artery disease in end stage renal disease. Atherosclerosis 2007;191(2):348 -354.

17. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease -mineral and bone disorder (CKD -MBD). Kidney disease: Improving global outcomes (KDIGO). Kidney Int 2009; 76 (Suppl): S113.

18. Adragão T, Pires A, Lucas C, Birne R, Magalhães L, Gonçalves M, Negrão AP.Vascular and valvular calcifi cations in dialysis patients: the same pathogenesis? Port J Nephrol Hypert 2007; 21(4): 293 -300.

19. Lehto S, Niskanen L, Suhonen M, et al. Medial artery calcifi cation. A neglected harbinger of cardiovascular complications in non -insulin -dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 1996; 16: 978 -983.

20. Okuno S, Maeno Y, Maekawa K, et al. Presence of abdominal aortic calcifi cation is signifi cantly associated with all -cause and cardiovascular mortality in maintenance hemodialysis patients. Am J Kidney Dis; 2007: 49: 417 -425.

21. Schlieper G, Krüger T, Djuric Z, et al. Calcifi cation of the arteriovenous fi stula predicts mortality in haemodialysis patients. Kidney Int 2008; 74: 1582 -1587.

22. Kauppila LI, Polak JF, Cupples LA, et al. New indices to classify location, severity and progression of calcifi c lesions in the abdominal aorta: a 25 -year follow -up study. Atherosclerosis 1997;132(2):245- -250.

23. Wilson PWF, Kauppila LI, O’Donnell CJ, et al. Abdominal aortic calcifi c deposits are an important predictor of vascular morbidity and mortality. Circulation 2001;103: 1529 -1534.

24. Bellasi A, Ferramosca E, Muntner P, et al. Correlation of simple imaging tests and coronary artery calcium measured by computed tomography in hemodialysis patients. Kidney Int 2006; 70: 1623 -1628. 25. Honkanen E, Kauppila L, Wikström B, et al; CORD study group. Abdominal aortic calcifi cation

in dialysis patients: results of the CORD study. Nephrol Dial Transplant 2008; 23: 4009 -4015.

26. Adragão T, PiresA, Branco P, Castro R, Oliveira A, Nogueira AC, BordaloJ, PrataMM. Ankle

brachial index, mortality and vascular calcifi cations in hemodialysis patients. NDT Plus 2010; 3 (Suppl 3): iii492. [Abstract Su545.]

27. Takahashi A, Takase H, Toriyama T, et al. Candesartan, an angiotensin II type -1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis – a randomized study. Nephrol Dial Transplant 2006; 21: 2507 -2512.

28. Cice G, Ferrara L, D’Andrea A, et al. Carvedilol increases two -year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo -controlled trial. J Am Coll Cardiol 2003; 41: 1438 -1444.

comme nta r y

http://www.kidney-international.org

© 2008 International Society of Nephrology

see original article on page 1582

Cardiovascular risk in dialysis